Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News UNITY Biotechnology Inc UBX

Healthcare Biotechnology
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging.... see more

Recent & Breaking News (NDAQ:UBX)

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

GlobeNewswire 10 days ago

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

GlobeNewswire 12 days ago

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire April 15, 2024

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

GlobeNewswire February 6, 2024

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

GlobeNewswire December 12, 2023

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire November 13, 2023

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

GlobeNewswire November 10, 2023

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

GlobeNewswire September 27, 2023

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

GlobeNewswire August 8, 2023

UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

GlobeNewswire June 21, 2023

UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates

GlobeNewswire May 9, 2023

UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

GlobeNewswire April 24, 2023

UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

GlobeNewswire April 23, 2023

UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

GlobeNewswire March 27, 2023

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

GlobeNewswire March 15, 2023

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

GlobeNewswire February 28, 2023

UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference

GlobeNewswire February 15, 2023

UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study

GlobeNewswire February 9, 2023

UNITY Biotechnology Reports Granting of New Employment Inducement Award

GlobeNewswire January 18, 2023

UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates

GlobeNewswire November 8, 2022